Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer-Reference-Cited by-同舟云学术

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Published:2019-03-21 Issue:1 Volume:21 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Kennedy Sean P.,Han Jeremy Z. R.,Portman Neil,Nobis Max,Hastings Jordan F.,Murphy Kendelle J.,Latham Sharissa L.,Cadell Antonia L.,Miladinovic Dushan,Marriott Gabriella R.,O’Donnell Yolande E. I.,Shearer Robert F.,Williams James T.,Munoz Amaya Garcia,Cox Thomas R.,Watkins D. Neil,Saunders Darren N.,Timpson Paul,Lim Elgene,Kolch Walter,Croucher David R.^ORCID

Funder

Science Foundation Ireland

Cancer Institute NSW

Irish Cancer Society

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-019-1127-y.pdf

Reference49 articles.

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.

2. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120–8.

3. Richard S, Selle F, Lotz JP, Khalil A, Gligorov J, Soares DG. Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc. 2016;88(Suppl 1):565–77.